A Broad Impact for Global Oncology

Global oncology demands attention, with approximately 9 million people dying from cancer annually. It provides an extraordinary opportunity to address the urgent need for cancer care and be a catalyst for solutions to address critical societal issues including the disruptive forces in and among countries involving the health of individuals and the planet, relationships among cultures, the digital revolution, inequality, and the sociopolitical conflict of globalism vs isolationism.  Read the article published online in JAMA Oncology

Job opportunity with the IAEA

Great opportunity to work at the IAEA! A 2-year global health position is for a Junior professional (JPO) in the Division of Human Health (NAHU) supported through the US government.   Click here for job listing. Apply through Argonne National labs.

April 30th deadline!


“I think the message is very simple: it’s wasteful not to invest in health”

The alarming report released by the WHO details the staggering drain that disease has on the African economy. It projects that by 2030, the loss in GDP could be almost $1.7 trillion unless ambitious goals to increase the investment in health care improvement are met. The report also highlights the large percentage (37%) that non-communicable diseases account for in this burden. The necessary shift to translate political commitments into investment is possible by implementing changes not only to treat disease but to promote good health and prevention.
Read more…

ICEC’s response to The Lancet, “Offline: Why has global health forgotten cancer?”

ICEC’s response to Richard Horton’s thoughtful commentary, “Offline: Why has global health forgotten cancer?” was published in The Lancet.

While prevention is critical, tackling cancer is about much more than just prevention. “The solution to the deficit of global cancer care is a systematic approach to build expertise, capacity, and capability using a sustainable model that recognizes the mutually beneficial links among cancer, the other non-communicable diseases, infectious diseases, and health-care systems, while also producing economic benefit”. Read more…

Developing Innovative, Robust and Affordable Medical Linear Accelerators for Challenging Environments

Motivated by stunning projections regarding the rise of cancer cases globally to 25 million cases in 2035 with 70% of those occurring in low- and middle- income countries, coupled with the paucity of access to radiotherapy treatment – an essential component of curative and palliative care – a group of individuals from the International Cancer Expert Corps (ICEC), Science and Technology Facilities Council (STFC UK), CERN and others, took on the challenge to meet the demands for cancer care focusing on the need to develop a medical linear accelerator to be used in resource-limited settings.  Read the Editorial in Clinical Oncology

Dr. C. Norman Coleman receives the the Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care

ICEC’s Senior Scientific Advisor, Dr. C. Norman Coleman, received the Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care. The award recognizes exceptional providers who are transforming cancer care.

The Stovall Award is awarded annually to individuals, organizations, or other entities who demonstrate innovation in improving cancer care for patients in America. NCCS created the Stovall Award in honor of Ellen Stovall, NCCS’ longtime CEO who passed away in 2016 due to cardiac complications from her cancer treatment.  Read more…

The fight against non-communicable disease in emerging economies

October 17, 2018

Charles Schmidt, a science writer for Nature, highlights that health-care providers in low- and middle-income countries are shifting their focus away from infections, and towards the bigger problems of diabetes and cardiovascular disease.

While cardiovascular diseases account for most NCD deaths, or 17.9 million people annually,  cancers account for (9.0 million), respiratory diseases (3.9million), and diabetes (1.6 million). These 4 groups of diseases account for over 80% of all premature NCD deaths. Read more…

HPV-related cancer rates are rising. So are vaccine rates — just not fast enough.

Cancers linked to the human papillomavirus have increased significantly over the last 15 years in the United States, with throat cancer now the most common HPV-related malignancy, the Centers for Disease Control and Prevention reported Thursday. More than 43,000 people developed HPV-associated cancer in 2015, compared with about 30,000 in 1999, the CDC said.

At the same time, the CDC said, HPV vaccination rates are rising — a trend that could eventually curb the increase in cancer cases  — But the rate is not rising fast enough, experts say. Nearly half of adolescents ages 13 to 17 in 2017 had received all the recommended doses for HPV vaccination, while two-thirds had received the first dose. Read the Washington Post article…

This is a challenge for those in Low-Income Countries LIC and Low- and Middle-Income Countries (LMIC) as well.  Gallagher, K. et al, in Vaccine, “Status of HPV vaccine introduction and barriers to country uptake” suggest that if one-dose HPV vaccination became viable, some of the significant barriers to scale-up and sustained use in LIC/LMIC may be overcome. (Perhaps the same for Upper-Income Countries?) The vaccine could prevent 90 percent of HPV-caused cancer cases every year.

Green Journal article, “ENLIGHT: European network for Light ion hadron therapy”

The article, “ENLIGHT: European network for Light ion hadron therapy” published in the most recent Radiotherapy and Oncology issue, chronicles 15 years of ENLIGHT, reflecting the power and need for collaboration. ENLIGHT has been extremely influential in its work related to hadron therapy (HT), including topics such as patient selection, clinical trials, technology, radiobiology, imaging and health economics. ENLIGHT was initiated through CERN and ESTRO and dealt with various disciplines such as (medical) physics and engineering, radiation biology and radiation oncology.   Read more